We have seen 119 institutional investors add shares of $BNTX stock to their portfolio, and 192 decrease their positions in their most recent quarter.

BioNTech SE ADR (NASDAQ:BNTX) stock is up 2.8% to trade at $825.41 at last glance, after an Evercore ISI upgrade to "outperform" from "in-line." The analyst in question also hiked its price target to ...

On Monday, June 2, Truist Securities analysts raised the price target on BioNTech SE (NASDAQ:BNTX) from $151 to $155 and kept a “Buy” rating. This decision came after the company entered into an ...

Investors might want to bet on BioNTech SE Sponsored ADR (BNTX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18, BioNTech SE (NASDAQ:BNTX) ...

Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical development across multiple solid tumors. The analyst notes that the data for ...

BioNTech SE ( ($BNTX) ) has provided an update. On December 18, 2025, BioNTech SE announced it had closed its acquisition of CureVac N.V., ...

Shares of BioNTech SE – ADR (NASDAQ:BNTX) fell 5.7% to $115.84 on Monday, part of a broader decline in vaccine stocks triggered by Moderna's updated revenue guidance for 2025, which fell below analyst ...

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company reported earnings per share of €1.08 compared to Wall Street’s estimate of 44 ...

I rate BioNTech SE a hold due to volatile financial performance, weak growth, and premium valuation. The company's financials are heavily reliant on COVID-19 vaccines, with declining demand impacting ...